Optimal Mid‑Range Dose for Anemia Treatment

What is Epobiocrin 4000 IU?

Epobiocrin 4000 IU is a standardized dose of recombinant human erythropoietin (epoetin alfa), used to treat moderate anemia—especially in patients with chronic kidney disease (CKD), chemotherapy‑induced anemia, or chronic illness. Each sterile pre-filled syringe contains 4000 international units, allowing effective hemoglobin response with fewer injections than low-dose regimens.

When to Use Epobiocrin 4000 IU?

• Moderate anemia correction: when dosages of 2000 IU are insufficient.
• Weekly dosing convenience: 4000 IU once weekly often replaces 2000 IU twice weekly.
• Ideal for outpatient/home therapy: efficient dosing for body weights 60–80 kg.
• Intermediate alternative: useful for patients transitioning between low (2000 IU) and high (10000 IU) dosing.

Composition and Presentation

A single 0.5 mL Epobiocrin syringe contains:

• Active Ingredient: Epoetin alfa – 4000 IU
• Excipients: Sodium chloride, sodium phosphate buffers, polysorbate 20, and water for injection.

The solution is clear, preservative‑free, packed in individual sterile syringes for accuracy and patient safety.

Mechanism of Action

Epoetin alfa binds to erythropoietin receptors on erythroid progenitor cells, triggering cell proliferation and differentiation, increasing red blood cell count and oxygen-carrying capacity, thus alleviating fatigue and improving quality of life.

Indications for 4000 IU Dose

Epobiocrin 4000 IU is indicated when moderate anemia requires moderate correction:

• CKD patients with hemoglobin levels around 8–9 g/dL
• Oncology patients with partial response to low-dose EPO
• HIV-associated anemia patients with mild to moderate anemia
• Long-term anemia management to maintain target Hb between 10–11 g/dL

Dosage & Administration

Starting Regimen

• Initial dose: 4000 IU once weekly, subcutaneously or intravenously
• For faster correction, may split into 2000 IU twice weekly

Dose Adjustments

• Monitor hemoglobin every 2–4 weeks
• Adjust dose ±25% depending on Hb response
• Reduce frequency if hemoglobin exceeds 12 g/dL

Maintenance Therapy

Once hemoglobin is stable (10–11 g/dL), dosing can be reduced to Epobiocrin 4000 IU every 10–14 days or switched to 2000 IU twice weekly based on response and body weight.

Pharmacokinetics

• Subcutaneous half-life: ~24 hours, peak absorption in 12–18 hours
• Intravenous half‑life: ~6–8 hours, faster action but shorter duration
• Bioavailability: ~20% via subcutaneous route

Safety and Side Effects

Common Adverse Effects

• Hypertension (10–25%)
• Headache or dizziness
• Injection site discomfort or redness

Serious Risks

• Thromboembolic events, especially if hemoglobin increases too rapidly
• Rare antibody-mediated PRCA (pure red cell aplasia)
• Excessive/rapid Hb rise—minimize cardiovascular risks

Monitoring

• Regular hemoglobin checks (every 2–4 weeks)
• Blood pressure monitoring mandatory
• Assess iron status periodically; supplement iron if needed

Contraindications & Warnings

• Hypersensitivity to epoetin alfa or excipients
• Uncontrolled hypertension
• History of thromboembolic events or PRCA
• Use in pregnancy or breastfeeding only if clearly needed

Clinical Evidence – 4000 IU Efficacy

Clinical studies show that 4000 IU weekly dosing effectively raises hemoglobin by 1–2 g/dL within 4–6 weeks in CKD patients without increasing injection frequency. Oncology studies demonstrate similar efficacy in managing chemotherapy-associated anemia and reducing transfusion requirements.

The post Epobiocrin (Epoetin alfa) solution for injection, 4000 IU #5 appeared first on MeDank Online Shop.

Injection for Severe Anemia and ESA Responders

What is Epobiocrin 10000 IU?

Epobiocrin 10000 IU is a high-dose recombinant human erythropoietin (epoetin alfa) formulation used in the treatment of severe or refractory anemia, especially in patients with chronic kidney disease (CKD), cancer-related anemia, chemotherapy-induced anemia, or anemia in HIV therapy. Each sterile pre‑filled syringe is calibrated to contain 10,000 international units (IU) of epoetin alfa and is designed for injection either subcutaneously or intravenously under strict medical supervision.

Why Choose Epobiocrin 10000 IU?

• High efficacy in severe anemia: Ideal when lower doses fail to raise hemoglobin.
• Reduced injection volume: One syringe often covers multiple weekly doses for patients above 80 kg.
• Convenient for outpatient or home therapy: Fewer syringes and injections.
• Essential for ESA hyporesponders: Used when patients show minimal response to 2000–5000 IU.

Key Benefits and Applications

Epobiocrin 10000 IU addresses anemia related to:

• Chronic kidney disease, including hemodialysis and peritoneal dialysis patients
• Chemotherapy-induced anemia in oncology patients
• HIV-associated anemia, especially in zidovudine-treated patients
• Preoperative anemia to reduce transfusion needs
• Patients with ESA hypo-responsiveness needing higher dosage

Composition and Product Packaging

Each 0.5 mL Epobiocrin syringe contains:

• Active Ingredient: Epoetin alfa – 10000 IU (recombinant human erythropoietin)
• Inactive Ingredients: Sodium chloride, polysorbate 20, thermostabilizers, water for injection

The solution is clear and colorless, supplied in a single-use sterile syringe to ensure safe, accurate dosing.

Mechanism of Action

Epoetin alfa mimics the physiologic effects of erythropoietin produced by kidneys. By binding to erythropoiesis-stimulating receptors on immature red blood cell precursors in bone marrow, it activates intracellular pathways that lead to proliferation, differentiation, and maturation of erythroid cells. This results in increased red blood cell mass, improved oxygen delivery, reduced fatigue, and better overall functional capacity.

Indications for 10000 IU Dose

Severe or Symptomatic Anemia in CKD

For hemoglobin < 8 g/dL in dialysis or nondialysis patients, a 10000 IU dose is often used to achieve faster control of anemia and reduce transfusion dependence.

Chemotherapy-Induced Severe Anemia

In oncology patients with severe anemia and limited response to conventional lower doses, 10000 IU enables more efficient correction while reducing injection frequency.

ESA Hyporesponse or Resistance

Patients who fail to respond to 2000–4000 IU may require a dose escalation to 10000 IU under supervision.

Dosage and Administration Guidelines

Starting Dose

• Usually 10000 IU once weekly, injected subcutaneously
• For rapid correction, initial dose may be split into 5000 IU twice per week

Dose Monitoring

• Monitor hemoglobin levels every 1–2 weeks initially
• Target hemoglobin is 10–12 g/dL; reduce or pause dose if > 12 g/dL
• Adjust dose by ±25% based on response

Maintenance Therapy

Once target hemoglobin is reached, dosing frequency may decrease to 10000 IU biweekly or adjust to lower frequency based on weight and response.

Pharmacokinetics and Pharmacodynamics

Following subcutaneous injection, epoetin alfa absorption gradually occurs, with peak plasma levels at 12–18 hours. Elimination half‑life is ~24 hours. Intravenous bioavailability is higher but associated with shorter half‑life (~8 hours) and requires more frequent injections.

Side Effect Profile

Common Side Effects

• Elevated blood pressure – occurs in 15–30%
• Injection site reactions: mild pain, erythema
• Flu-like symptoms: fatigue, arthralgia

Serious Risks

• Thromboembolic events (DVT, PE, stroke), especially at high Hb levels
• Pure red cell aplasia (rare antibody-mediated PRCA)
• Severe hypertension requiring dose reduction

Contraindications and Safety Precautions

• Known hypersensitivity to epoetin alfa or any component
• Uncontrolled hypertension must be stabilized before using
• History of PRCA or thrombotic events
• Pregnancy and breastfeeding only if benefit outweighs risks

Key Clinical Trials Supporting 10000 IU Use

Multiple Phase III trials in dialysis and oncology patients have shown that once-weekly high-dose epoetin alfa (including 10000 IU) effectively increases hemoglobin by an average of 2–3 g/dL within 4–6 weeks. These doses were generally well tolerated; hypertension was the most notable adverse event.

The post Epobiocrin (Epoetin alfa) solution for injection, 10000 IU #5 appeared first on MeDank Online Shop.

What is Epobiocrin 2000 IU?

EPOBIOCRIN 2000 IU is a therapeutic preparation of recombinant human erythropoietin (epoetin alfa) designed to treat various types of anemia—especially anemia due to chronic kidney disease (CKD), chemotherapy-induced anemia, or anemia associated with HIV infection. Each pre-filled syringe contains 2000 international units (IU) of epoetin alfa in a sterile solution, intended for subcutaneous or intravenous administration under medical supervision.

Why Use Epoetin Alfa 2000 IU?

• Effective in CKD-related anemia: helps stabilize hemoglobin and reduce transfusion dependency in dialysis patients.
• Cancer therapy support: helps oncology patients maintain acceptable hemoglobin during chemotherapy.
• Improves energy and stamina: often restores vitality, reduces fatigue and improves quality of life.
• Preoperative anemia management: used before major surgeries to minimize blood transfusion needs.
• Supports HIV patients: especially useful with zidovudine-induced anemia.

Composition and Presentation

Each 1 mL pre-filled syringe of Epobiocrin contains:

• Active Ingredient: Epoetin alfa — 2000 IU (recombinant human erythropoietin)
• Inactive Ingredients: Sodium chloride, sodium phosphate monobasic, sodium phosphate dibasic, polysorbate 20, and water for injection.

The solution is clear, colorless, and free from visible particles. It is supplied in individual sterile syringes to ensure aseptic administration.

Mechanism of Action

Epoetin alfa acts by binding to erythropoietin receptors on erythroid progenitor cells in the bone marrow. This binding triggers intracellular signaling that promotes proliferation and differentiation of erythroid precursor cells into mature red blood cells (RBCs). The increase in RBC count improves oxygen delivery to tissues, alleviates symptoms of anemia such as fatigue, weakness, and dyspnea, and supports overall physical performance.

Clinical Applications of 2000 IU Dose

The 2000 IU vial or syringe dosage is typically used as a maintenance or starting dose in moderate anemia. When administered subcutaneously or intravenously, doses vary depending on body weight, baseline hemoglobin, and clinical response. It is favored for outpatient and home-use settings due to its convenient dosing and reduced injection volume.

Chronic Kidney Disease (CKD)

Patients with CKD, especially those not on dialysis, often develop anemia due to reduced endogenous erythropoietin production. Epobiocrin 2000 IU is often prescribed to:

• Elevate hemoglobin levels to target range (10–12 g/dL).
• Manage anemia symptoms such as fatigue and cognitive impairment.
• Reduce need for red blood cell transfusions.

Dosing typically starts at approximately 50–100 IU/kg three times weekly until hemoglobin response is observed, followed by dose adjustments to maintain stability.

Cancer‑and Chemotherapy‑Induced Anemia

Many oncology patients experience anemia as a side effect of chemotherapy. Epobiocrin can be used to:

• Reduce transfusion requirements.
• Maintain hemoglobin at safe and tolerable levels.
• Improve patient endurance and ability to complete chemotherapy cycles.

HIV‑Associated Anemia

Patients on zidovudine (AZT) therapy often develop anemia. Epobiocrin helps:

• Counteract zidovudine-induced bone marrow suppression.
• Maintain hemoglobin and reduce risk of dose reductions or treatment interruptions.

Dosage Recommendations

Epoetin alfa dosing requires careful adjustment and monitoring:

Initial Dosage

• Typically 50‑100 IU/kg body weight, administered subcutaneously or intravenously three times per week.
• For a 70 kg adult, this equals approximately 140,000 IU per week, often divided into doses.

Monitoring and Dose Adjustment

• Target hemoglobin: 10–12 g/dL. Exceeding 12 g/dL may increase risk of cardiovascular events.
• Adjust dosage in increments of 25% based on hemoglobin response every 2–4 weeks.
• Maintain dose if hemoglobin rises by 1–2 g/dL over four weeks. Decrease dose if hemoglobin rises too quickly.

Maintenance Therapy

• Once stable hemoglobin is achieved, switch to maintenance dosing (e.g., 25–50 IU/kg once or twice weekly).
• Continue regular hemoglobin monitoring (every 4‑6 weeks).
• Ensure adequate iron stores—supplement iron if ferritin <100 ng/mL or transferrin saturation <20%.

Pharmacokinetics

Epoetin alfa has characteristic kinetics depending on route of administration:

• Half-life: Approximately 4–6 hours after intravenous injection; about 24 hours after subcutaneous administration.
• Bioavailability: ~20% after subcutaneous injection compared to intravenous route.
• No cumulative accumulation: Serum concentrations remain stable with repeated dosing.

Side Effects and Safety Profile

Common Adverse Events

• Hypertension (especially in patients with pre-existing blood pressure issues).
• Headache and dizziness.
• Flu‑like symptoms (fever, chills, myalgia).
• Injection site reactions (erythema, pain).

Rare but Serious Risks

• Thromboembolic events (deep vein thrombosis, pulmonary embolism, stroke).
• Pure red cell aplasia (PRCA) in rare cases of anti‑epoetin antibody formation.
• Excessive hemoglobin rise may increase cardiovascular mortality.

Management & Monitoring

• Regular monitoring of hemoglobin levels every 2–4 weeks during dose adjustments.
• Monitor blood pressure and adjust antihypertensive therapy if needed.
• Iron status markers (ferritin, transferrin saturation) should be checked periodically.

Contraindications & Precautions

• Hypersensitivity to epoetin alfa or any excipient.
• Uncontrolled hypertension (blood pressure should be stabilized before starting therapy).
• Patients with active malignancy should be carefully evaluated, as zidovudine may influence response.
• Pregnant or breastfeeding women—use only if benefits outweigh risks and under medical supervision.

Special Patient Populations

Elderly Patients

Use caution in older adults, especially those with cardiovascular comorbidities; dose and hemoglobin targets should be conservative.

Children & Adolescents

Dosing is weight-based; pediatric data are limited, so therapy should be individualized and supervised by a pediatric hematologist.

Clinical Trial Evidence

Multiple clinical studies demonstrate that epoetin alfa (2000 IU dosage range) effectively improves hematologic parameters in CKD and chemotherapy-induced anemia. In randomized trials, patients receiving EPO demonstrated: reduced transfusion needs, improved fatigue scores, and better exercise tolerance, compared to controls. Safety signals included mild hypertension and rare thromboembolic events.

How to Administer Epobiocrin 2000 IU

1. Allow syringe to reach room temperature before injection.
2. Wipe injection site (abdomen or thigh) with alcohol swab; rotate sites.
3. Inject slowly; discard syringe after single use.
4. Store unused syringes refrigerated (+2–8 °C), do not freeze.

Self‑Administration Tips

• Follow healthcare provider instructions exactly.
• Use proper disposal containers for sharps.
• Keep track of injection dates to avoid missed or duplicate doses.

Drug Interactions

No direct drug interactions are known; however:

• Concurrent use of iron supplements may be required to optimize response.
• Anti-hypertensive therapy may be needed to manage elevated blood pressure.
• Caution with pro-coagulant drugs due to thromboembolic risk.

Storage and Handling

• Store refrigerated between +2 °C and +8 °C.
• Do not freeze or shake the syringe.
• Protect from light.
• Discard unused portion after puncture; do not reuse syringe.

Frequently Asked Questions (FAQ)

Can Epobiocrin be taken orally?

No, it must be injected subcutaneously or intravenously. The protein would be degraded in the digestive tract.

How soon will I see results?

Hemoglobin typically increases within 2–6 weeks of starting therapy, depending on baseline conditions and iron status.

Is blood pressure monitoring necessary?

Yes. Elevated blood pressure is a common side effect and should be managed appropriately.

Availability and Legal Status

Epobiocrin is a prescription-only medication, approved in many countries including European Union nations, UAE, India, and other regions. Availability and brand name may differ locally; purchasing should be done through licensed pharmacies or medical providers.

Summary

EPOBIOCRIN 2000 IU (epoetin alfa) is a critically important biologic for treating anemia due to CKD, chemotherapy, HIV infection, or surgical preparation. Its precise dosing (2000 IU), predictable pharmacokinetics, and documented clinical efficacy make it a mainstay in anemia management. Safe use requires medical oversight, regular hemoglobin monitoring, and appropriate iron supplementation.

If you’d like a PDF or styled web block version of this description, or additional sections (e.g. cost comparisons, patient testimonials, regulatory approvals), just let me know.

The post Epobiocrin (Epoetin alfa) solution for injection, 2000 IU #5 appeared first on MeDank Online Shop.

Composition

• Active ingredient: Cabergoline 1 mg per tablet.
• Excipients: lactose, leucine, magnesium stearate, plus standard non‑active fillers.

Description

Cabergoline Teva is a long‑acting dopamine D₂ receptor agonist belonging to the ergot alkaloid class. Available as scored white tablets (1 mg strength), typically supplied in blister packs of 2, 8, 30, or 90 tablets. Designed for once‑ or twice‑weekly dosing due to its prolonged half‑life (~63‑69 hours), it is indicated primarily for treating hyperprolactinemia, prolactinomas, and related hormonal disorders.

Pharmacological Properties

Cabergoline exerts its therapeutic effect by high‑affinity partial agonism at dopamine D₂ receptors in the pituitary lactotrophs, suppressing prolactin secretion. It also exhibits activity at D₃, 5‑HT₁A, and 5‑HT₂ receptors, and α₂‑adrenergic receptors, but clinical effects are mediated mainly via D₂ agonism. Minimal central sedative action makes it preferable over older dopamine agonists.

Indications

• Hyperprolactinemia (idiopathic or due to pituitary adenomas/prolactinomas)
• Galactorrhea and menstrual irregularities caused by excess prolactin
• Infertility linked to prolactin excess, especially in PCOS or prolactinoma
• Off‑label use: adjunct in reducing risk of ovarian hyperstimulation syndrome during IVF

Dosage and Administration

• Initial adult dose: 0.5 mg once or twice weekly.
• Titration: increase by 0.5 mg increments every 4 weeks as needed to achieve normoprolactinemia (max ~1 mg/week in most patients).
• Maintenance: often ≤1 mg/week in divided doses.
• Monitor prolactin levels periodically; consider MRI for tumor size evaluation.

Side Effects

• Mild and transient: nausea, headache, dizziness, abdominal discomfort.
• Less common: hypotension, peripheral edema, depression, fatigue.
• Rare but serious (at high/duration doses): valvular fibrosis, pulmonary/peritoneal fibrosis, arrhythmias.

Side effects are dose-dependent and often attenuate with gradual titration. Rains & Molitch, 1995 reported rapid prolactin suppression with few discontinuations (<4 %).

Contraindications

• Allergy to ergoline-derived agents
• Uncontrolled hypertension or known valvular heart disease
• History of pulmonary, pleural, or retroperitoneal fibrosis
• Severe hepatic impairment

Precautions

• Baseline echocardiography recommended before long-term therapy to rule out valvulopathy.
• Slow dose escalation reduces early adverse effects.
• Discontinue temporarily prior to pregnancy; use bromocriptine instead if conception is planned.
• Monitor mood changes and impulse-control behaviors, especially with long-term use.

Interactions

• Concomitant ergot alkaloids should be avoided.
• Metabolism is minimally CYP450‑dependent, but caution advised when co-administered with CYP3A4 inhibitors (e.g., ketoconazole, erythromycin).
• Antipsychotics and metoclopramide may antagonize effects.
• Antihypertensives may exacerbate hypotension risk.

Overdose

Overdose may manifest as severe hypotension, nausea, syncope, hallucinations, or arrhythmia. Management includes immediate discontinuation, symptomatic support, fluid resuscitation, and monitoring.

Storage

• Store tablets at room temperature (15–25 °C).
• Protect from moisture, light, and heat.
• Keep out of reach of children.

Mechanism of Action

Cabergoline acts as a potent agonist at dopamine D₂ receptors, inhibiting adenylate cyclase and reducing intracellular cAMP in lactotrophs, thereby suppressing prolactin gene transcription and secretion. Its long half-life supports intermittent dosing schedules.

Clinical Studies and Evidence

A landmark retrospective review of 455 hyperprolactinemic patients showed normalization of prolactin in ~84% of bromocriptine-intolerant and ~70% of resistant cases using cabergoline (median 1.0 mg/week) with only ~3.9% discontinuation due to side effects. Verhelst et al., 1999

In a prospective study, high-dose cabergoline normalized prolactin and hypogonadism in nearly all subjects with macroadenomas, demonstrating efficacy regardless of baseline tumor size. Ono et al., 2008

Use in Special Populations

In reproductive-aged women, cabergoline supports restoration of ovulation and improves fertility outcomes. Systematic reviews confirm its tolerability and superior dosing convenience vs bromocriptine.

For athletes and physically active professionals, cabergoline does not exhibit performance‐enhancing properties and is allowed under WADA; however, due to hypotensive effects, caution is advised prior to competition.

Comparison with Other Therapies

Compared to bromocriptine, cabergoline offers higher efficacy, less frequent dosing, and fewer gastrointestinal side effects. Quinagolide is an alternative D₂ agonist but lacks long-term safety data outside Europe. Cabergoline remains the first-line agent in international endocrine guidelines.

Summary

Cabergoline Teva 1 mg is a high-affinity dopamine agonist indicated for hyperprolactinemia and related hormonal disorders. It is highly effective, tolerable, and convenient for long-term use. Use requires baseline and follow-up echocardiography, gradual titration, and monitoring of prolactin levels. The risk of valvulopathy is minimal at doses used for endocrine indications. Therapeutic use should be supervised by an endocrinologist.

The post Cabergoline (Teva) 1 mg appeared first on MeDank Online Shop.

Description

Laennec (Original) is a specialized injectable solution developed by Japan Bio Products Co., Ltd. (JBP), based on hydrolyzed human placenta extract. Widely used in regenerative and functional medicine, Laennec is globally recognized for its potential benefits in liver support, skin rejuvenation, immune modulation, and systemic revitalization.

Composition

• Human Placenta Hydrolysate – 112 mg per 2 ml ampoule
• Excipients: Sodium chloride, Water for injection

The hydrolysate contains peptides, amino acids, nucleic acids, enzymes, vitamins, cytokines, and trace elements derived from screened and purified human placental tissue, following Japanese GMP standards.

Pharmacological Properties

• Hepatoprotective: Improves liver enzyme profiles and supports regeneration of hepatocytes.
• Immunomodulatory: Enhances immune cell activity and reduces systemic inflammation.
• Anti-aging: Stimulates collagen production, skin elasticity, and cellular turnover.
• Antioxidant: Reduces oxidative stress markers and supports metabolic detoxification.

Indications

Laennec is indicated for the following therapeutic and supportive uses:

• Chronic liver diseases (e.g., hepatitis, steatosis)
• Anti-aging and skin rejuvenation therapy
• Fatigue and burnout syndromes
• Immunosuppression and frequent infections
• Menopausal and perimenopausal symptoms
• Adjunct therapy in dermatological disorders

Dosage and Administration

• General regimen: 2 ml (1 ampoule) intramuscularly, 2–3 times per week
• Therapeutic protocols: Dosage may be increased to 4–6 ml weekly under physician supervision
• Administer via deep intramuscular injection (e.g., gluteal region)

Laennec is not intended for intravenous or subcutaneous use. All procedures should be performed by licensed medical professionals.

Contraindications

• Known hypersensitivity to any component of the formulation
• Pregnancy and lactation (unless prescribed by a physician)
• Autoimmune disease (use only under specialist supervision)

Precautions

• Conduct allergy testing if history of hypersensitivity is unknown
• Disclose all current medications and chronic conditions to your physician
• Not suitable for self-injection or use without clinical guidance

Side Effects

Most side effects are mild and transient. Reported reactions include:

• Redness or soreness at injection site
• Headache, fatigue, or mild fever after injection
• Rare: allergic reactions (rash, swelling, dyspnea)

In case of suspected hypersensitivity, discontinue use and seek medical attention.

Interactions

No specific drug interactions have been documented. However, due to the bioactive nature of Laennec, caution is advised when used concurrently with:

• Immunosuppressants or corticosteroids
• Hormone-modulating therapies

Overdose

Overdose risk is minimal when used intramuscularly and as prescribed. Excessive dosing may increase the risk of hypersensitivity reactions. In such cases, discontinue use and consult a physician immediately.

Storage

• Store between 2°C and 25°C (do not freeze)
• Keep away from direct sunlight, heat, and moisture
• Use ampoule immediately after opening

Packaging

Each box contains 10 ampoules of 2 ml Laennec (Original) solution, individually sealed for sterile use.

Manufacturer

Japan Bio Products Co., Ltd. (JBP), Tokyo, Japan — a leading innovator in cell therapy and placental pharmacology, operating under rigorous quality control and GMP certification.

Scientific References

• Miyazaki et al. – Effects of human placental extract on liver function
• Kimura et al. – Immunomodulatory effects of placental extract

The post Laennec (Original) – 1 ampoule 2 ml. appeared first on MeDank Online Shop.

Composition

Each vial of Jintropin contains 10 IU of somatropin, a recombinant human growth hormone, in a 1 ml solution. The package includes 5 vials. Additional excipients may include mannitol and phosphate buffer.

Description

Jintropin is a synthetic form of human growth hormone produced using recombinant DNA technology. It is structurally identical to the natural hormone produced by the pituitary gland and is used to promote growth, regeneration, and cellular repair in individuals with growth hormone deficiencies.

Indications

• Treatment of growth failure in children due to inadequate secretion of endogenous growth hormone.
• Adult growth hormone deficiency (AGHD), either of childhood-onset or adult-onset origin.
• May also be prescribed off-label for cachexia, muscle wasting in HIV/AIDS, or anti-aging purposes, under medical supervision.

Contraindications

• Hypersensitivity to somatropin or any formulation components.
• Active malignancy or proliferative retinopathy.
• Children with closed epiphyses (growth plates).
• Critical illness due to surgery, trauma, or acute respiratory failure.
• Severe obesity or respiratory impairment in Prader-Willi syndrome patients.

Administration and Dosage

Jintropin is administered subcutaneously, usually once daily. Dosage is individualized based on weight, age, condition, and therapeutic response:

• Children: 0.025–0.035 mg/kg/day
• Adults: Start at 0.15–0.3 mg/day, titrated up to a maximum of 1 mg/day depending on tolerance

Injection sites should be rotated to avoid lipodystrophy.

Side Effects

• Common: Injection site reactions, headache, joint or muscle pain, edema.
• Serious: Intracranial hypertension, pancreatitis, scoliosis progression, slipped capital femoral epiphysis, glucose intolerance, hypothyroidism.

Drug Interactions

Jintropin may interact with:

• Corticosteroids: may inhibit growth-promoting effect.
• Insulin or oral hypoglycemics: dosage adjustment may be necessary due to altered glucose metabolism.
• Cytochrome P450-metabolized drugs: altered clearance of coadministered medications.

Storage

• Store unopened vials in a refrigerator at 2–8°C (36–46°F).
• Do not freeze.
• Protect from light and keep in original packaging.
• Use immediately after reconstitution; discard any unused portion.

Overdose

Acute overdose may lead to hypoglycemia followed by hyperglycemia. Chronic overdose may cause acromegaly/gigantism and other metabolic abnormalities. Seek immediate medical attention in case of suspected overdose.

Precautions

• Monitor thyroid function and adjust therapy if necessary.
• Evaluate for potential glucose intolerance or diabetes development.
• Screen patients for scoliosis, especially in pediatric cases.
• Not indicated for performance enhancement or cosmetic use without medical necessity.

Warnings

• Monitor for signs of increased intracranial pressure.
• Do not use in patients with active neoplastic disease.
• Discontinue treatment in case of any signs of malignancy recurrence.

Disposal

Dispose of unused or expired Jintropin vials in accordance with local pharmaceutical waste regulations. Do not flush or pour into drains.

Pregnancy and Lactation

Limited data available. Use only if the potential benefit justifies the potential risk to the fetus or infant. Consult a healthcare provider before use.

Manufactured by

GeneScience Pharmaceuticals Co., Ltd. — a biopharmaceutical company specializing in the research and development of recombinant human growth hormone (rhGH) therapies.

Scientific References

• Clinical use of growth hormone in adults and children
• Somatropin – StatPearls (NCBI)

The post Jintropin vials 10 IU, 1 ml, #5 appeared first on MeDank Online Shop.

Composition

Each Somaliq Pen 60IU contains 60 International Units (IU) of the active substance Insulin Glulisine, a rapid-acting insulin analog. Other components include metacresol, sodium chloride, tromethamine, polysorbate 20, hydrochloric acid and/or sodium hydroxide (for pH adjustment), and water for injection.

Description

Somaliq Pen 60IU is a prefilled, disposable insulin pen designed for subcutaneous injection. Insulin glulisine is a recombinant human insulin analog with a rapid onset and short duration of action, used for the control of blood glucose in diabetic patients.

Pharmacological Action

Insulin glulisine mimics the body’s natural insulin response after meals. It begins to act within 15 minutes of injection and has a shorter duration of action compared to regular human insulin. It facilitates cellular glucose uptake and inhibits hepatic glucose output, thus lowering blood glucose levels.

Indications

• Type 1 Diabetes Mellitus
• Type 2 Diabetes Mellitus in adults and children requiring rapid-acting insulin to improve glycemic control

Dosage and Administration

• Administer subcutaneously into the abdominal wall, thigh, or upper arm.
• Injection should be given 15 minutes before or immediately after a meal.
• Dosage must be individualized based on blood glucose monitoring and glycemic targets.
• May be used in combination with long-acting insulin or oral antidiabetic medications.

Contraindications

• Hypersensitivity to insulin glulisine or any excipients in the formulation
• During episodes of hypoglycemia

Warnings and Precautions

• Monitor for hypoglycemia, especially with changes in diet, exercise, or insulin regimen
• Use with caution in patients with renal or hepatic impairment
• Rotate injection sites to reduce risk of lipodystrophy
• Use cautiously in patients with hypoglycemia unawareness
• Adjust dose when switching between insulin types or brands

Drug Interactions

• May potentiate hypoglycemia: Oral antidiabetic agents, ACE inhibitors, salicylates, sulfonamides, alcohol
• May reduce effect of insulin: Corticosteroids, diuretics, sympathomimetics, thyroid hormones, oral contraceptives
• Beta-blockers may mask symptoms of hypoglycemia

Side Effects

• Very common: Hypoglycemia
• Common: Injection site reactions (pain, redness, swelling), lipodystrophy
• Less common: Weight gain, allergic reactions, rash
• Rare but serious: Anaphylaxis, severe hypoglycemia, hypokalemia

Overdose

Overdose may cause severe and prolonged hypoglycemia. Immediate treatment includes consumption of sugar or glucose. In severe cases (e.g., unconsciousness), emergency medical attention is required with intravenous glucose or glucagon injection.

Use in Pregnancy and Lactation

• Pregnancy Category B: No evidence of harm in animal studies, but use only if clearly needed during pregnancy
• Unclear if excreted in breast milk; use caution during lactation

Storage

• Store unopened pens in a refrigerator (2°C–8°C). Do not freeze.
• After first use, store at room temperature (<30°C) and discard after 28 days.
• Protect from direct heat and light. Keep out of reach of children.

Scientific References

• Insulin glulisine pharmacokinetics – PubMed
• Insulin Therapy in Diabetes – NCBI

The post Somaliq Pen 60IU appeared first on MeDank Online Shop.

Composition

Each Epaviten pack contains 6 ampoules and 6 vials. The ampoules typically include a blend of essential vitamins such as B1, B2, B6, B12, C, D, and E, along with minerals like calcium, iron, magnesium, and zinc. Some formulations may also contain glucose, amino acids, or sodium lactate. The vials contain sterile water or a buffered diluent for dissolving the contents of the ampoules prior to administration.

Indications

• Treatment and prevention of vitamin and mineral deficiencies
• Supplementation during pregnancy, lactation, or growth phases
• Post-operative recovery or recovery from prolonged illness
• Support in chronic illness or stress-induced nutritional deficiency
• Adjunct support in cases of poor nutrition or restrictive diets

Dosage and Administration

• Standard dosage: One ampoule dissolved in one vial, taken once daily orally
• Administration: Shake well before use. Consume immediately after preparation
• Recommended with food to aid absorption and reduce gastric irritation
• Do not exceed recommended dosage unless directed by a healthcare provider

Contraindications

• Hypersensitivity to any of the components
• Hypercalcemia or hypercalciuria
• Severe renal impairment or active nephrolithiasis
• Use with caution in patients already taking multivitamin or mineral supplements

Side Effects

• Gastrointestinal discomfort: nausea, diarrhea, abdominal pain
• Rare: hypersensitivity reactions such as rash or itching
• Excessive doses may lead to vitamin toxicity (e.g., hypervitaminosis A or D)

Warnings and Precautions

• Not a substitute for a balanced diet
• Use in pregnancy or lactation should be under medical supervision
• Inform physician of any concurrent medications
• Do not mix with other injectable or oral solutions unless approved

Drug Interactions

• May interact with antibiotics (e.g., tetracyclines), anticonvulsants, and iron supplements
• Calcium and magnesium may affect absorption of certain drugs (e.g., bisphosphonates, fluoroquinolones)
• Inform healthcare provider of all vitamins, minerals, and herbal products being used

Overdose

In case of overdose, symptoms may include gastrointestinal distress, hypervitaminosis, or hypermineralemia. Severe cases may lead to confusion, cardiac arrhythmias, or seizures (particularly in hypercalcemia). Immediate medical attention is required. Treatment is symptomatic with hydration and electrolyte monitoring.

Storage

• Store at room temperature (15°C – 25°C)
• Protect from light and moisture
• Keep out of reach of children
• Use immediately after mixing

Scientific References

• The Role of Multivitamin and Mineral Supplementation in Clinical Practice – NCBI
• Multivitamins in health promotion: meta-analysis of randomized controlled trials – PubMed

The post Epaviten 6 ampoules + 6 vials appeared first on MeDank Online Shop.

Composition

Each 1 ml ampoule contains:

• Testosterone Propionate – 50 mg
• Excipients: Benzyl Alcohol (preservative), Benzyl Benzoate (solubilizer), Refined Peanut Oil (vehicle)

Indications

Testosterone Propionate is indicated for testosterone replacement therapy in males with confirmed testosterone deficiency due to congenital or acquired conditions, including:

• Primary hypogonadism (testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, or orchiectomy)
• Hypogonadotropic hypogonadism (congenital or acquired)
• Delayed puberty in adolescent males (under specialized supervision)
• Inoperable metastatic breast cancer in females (as palliative treatment)

Mechanism of Action

Testosterone Propionate is a short-acting ester of the endogenous androgen testosterone. It acts via androgen receptors to stimulate protein synthesis, muscle growth, erythropoiesis, libido, and the development/maintenance of male secondary sexual characteristics. It also modulates luteinizing hormone (LH) and follicle-stimulating hormone (FSH) through negative feedback on the hypothalamic-pituitary-gonadal axis.

Dosage and Administration

• Route: Deep intramuscular injection into the gluteal muscle
• Typical adult dosage: 25–50 mg every 2–3 days
• Adjustment: Based on serum testosterone levels and clinical response
• Monitoring: Evaluate testosterone levels, hematocrit, liver function, and PSA regularly

Contraindications

• Known or suspected carcinoma of the prostate or male breast
• Hypersensitivity to testosterone or formulation excipients
• Women who are pregnant or may become pregnant (teratogenic risk)
• Severe hepatic, cardiac, or renal impairment (due to fluid retention risk)

Warnings and Precautions

• Monitor hematocrit (risk of polycythemia), especially in elderly patients
• Use with caution in patients with sleep apnea, benign prostatic hyperplasia (BPH), or hypertension
• May increase risk of prostate hypertrophy or prostate cancer – monitor PSA levels
• May impair fertility due to suppression of gonadotropins

Adverse Reactions

• Local: Pain, redness, or swelling at injection site
• Systemic: Gynecomastia, oily skin, acne, increased libido or aggression, fluid retention
• Endocrine: Suppression of spermatogenesis, alterations in lipid profile, polycythemia

Drug Interactions

• Oral anticoagulants: Increased anticoagulant effect – monitor INR
• Insulin or antidiabetics: Enhanced hypoglycemic response
• Glucocorticoids: Increased risk of fluid retention and edema

Overdose

Acute overdose is unlikely to cause life-threatening events. In case of excessive dosing, symptoms may include increased hematocrit, mood changes, or libido fluctuations. Therapy should be interrupted and resumed at a lower dose after clinical assessment.

Clinical Evidence

• Testosterone Therapy in Men With Hypogonadism – NCBI
• Endocrine Society Clinical Guidelines on Testosterone – JCEM

Storage

• Store at 15–25°C (59–77°F)
• Protect from light and moisture
• Keep out of reach of children
• Do not use if solution is cloudy or contains particles

Disclaimer

This product is a prescription-only medication. It should only be used under the supervision of a qualified healthcare provider after confirmation of testosterone deficiency. Do not use for body-building or performance enhancement without medical justification, as misuse can result in serious health risks.

The post Testosterone Propionate 50 mg/ml. #5 appeared first on MeDank Online Shop.

Composition

Pregnyl contains the active substance human Chorionic Gonadotrophin (hCG), with each vial delivering 1500 IU. It is derived from the urine of pregnant women and purified for medical use. Inactive ingredients include mannitol and sodium phosphate, which help stabilize the solution. Each pack includes 3 vials.

Indications

• Induction of ovulation in women with infertility due to anovulation
• Support of the luteal phase in assisted reproductive technology (ART) protocols
• Treatment of male infertility due to hypogonadotropic hypogonadism (low sperm count)
• Stimulation of testosterone production in delayed puberty in boys

Dosage and Administration

Pregnyl is administered by intramuscular or subcutaneous injection. Doses should always be determined by a physician. Typical regimens include:

• Women (Ovulation Induction): 5,000 to 10,000 IU one day after the last dose of follicle-stimulating hormone (FSH) or menotropins
• Men (Hypogonadism): 500 to 1000 IU three times weekly for 3 weeks, followed by the same dose twice weekly for another 3 weeks
• Pubertal Boys: Dosage and frequency individualized by physician

Contraindications

• Known hypersensitivity to hCG or any component of the product
• Women with ovarian enlargement not caused by PCOS
• Uncontrolled thyroid or adrenal gland disorders
• Unexplained uterine bleeding
• Androgen-dependent tumors (e.g., prostate cancer in men)

Warnings and Precautions

• May increase the risk of multiple gestation (e.g., twins or triplets)
• Careful monitoring is advised in patients with heart disease, renal disease, migraines, asthma, or epilepsy
• Use in adolescent boys should be supervised to avoid premature epiphyseal closure
• Monitor ovarian response to avoid ovarian hyperstimulation syndrome (OHSS)

Side Effects

Common side effects include:

• Headache
• Irritability
• Fatigue
• Localized swelling or pain at the injection site

Serious but less common effects include:

• Ovarian hyperstimulation syndrome (OHSS)
• Weight gain
• Lower abdominal or pelvic pain
• Edema or shortness of breath

Interactions

No major interactions are widely documented, but concurrent use with gonadotropins or fertility medications may amplify ovarian response. Always inform your physician of any ongoing medications or supplements.

Storage

• Store in a refrigerator between 2°C and 8°C (36°F to 46°F)
• Do not freeze
• Keep vials in the original packaging to protect from light
• Keep out of reach of children

Scientific References

• Practice Committee of the ASRM. Use of hCG in infertility treatment – PubMed
• Pregnyl Prescribing Information – Drugs.com

Conclusion

Pregnyl is an effective medication used in the treatment of infertility in both men and women, as well as in the stimulation of testosterone in boys with delayed puberty. It must be administered under medical supervision with regular monitoring to ensure safety and efficacy.

The post Pregnyl vials, 1500 IU, #3 appeared first on MeDank Online Shop.